Selective activation of mitochondrial ALDH2 is sufficient to improve the HF outcome by reducing the toxic effects of aldehydic overload on mitochondrial bioenergetics and reactive oxygen species generation, suggesting that ALDH2 activators, such as Alda-1, have a potential therapeutic value for treating HF patients.

The pandemic caused by COVID-19 has drastically affected the health and well-being of the world's population. However, early detection is essential not only for the treatment and cure of patients, but also for public health, ensuring the isolation of patients. So far, several screening methods have been introduced for the diagnosis of COVID-19, including the analysis of medical images. Recent studies prove that Artificial Intelligence can be useful for a fast and accurate diagnosis. Therefore, the mini-course aims to develop a web application for the diagnosis of COVID-19, through chest radiography images, using concepts, techniques and tools of Artificial Intelligence and Digital Image Processing, being able to provide a second opinion to specialists. ResumoA pandemia causada pela COVID-19 afetou drasticamente a saúde e o bem-estar da população mundial. No entanto, a detecção precoce é essencial não só para o tratamento e cura dos pacientes, mas também para a saúde pública, garantindo o isolamento dos pacientes. Até o momento, vários métodos de triagem foram introduzidos para o diagnóstico da COVID-19, incluindo a análise de imagens médicas. Estudos recentes comprovam que a Inteligência Artificial pode ser útil para um diagnóstico rápido e preciso. Portanto, o minicurso tem como objetivo desenvolver uma aplicação web para o diagnóstico da COVID-19, por meio de imagens de radiografia do tórax, usando conceitos, técnicas e ferramentas de Inteligência Artificial e Processamento de Imagens Digitais, podendo fornecer uma segunda opinião aos especialistas.

: Our data suggest that pneumonectomy is not associated with early pulmonary hypertension; gentle fluid resuscitation improves cardiovascular performance and is not associated with an increase in right ventricular pressure.

Introduction:Atherosclerosis is now widely recognized as a multifactorial disease with outcomes that arise from complex factors such as plaque components, blood flow, and inflammation. The locations most frequently affected by carotid atherosclerosis are the proximal internal carotid artery (ie, the origin) and the common carotid artery bifurcation. Therefore, the objective of the current study is to conduct a systematic review with network meta-analysis to compare the effects of statins classes on carotid disease (CD) patients.Methods and analysis: Randomized clinical trials (RCTs) and observational studies published in English up to 31 December 2018, and which include direct and/ or indirect evidence, will be included. Studies will be retrieved by searching four electronic databases and cross-referencing. Dual selection and abstraction of data will occur. The primary outcome will all-cause mortality, new event of acute myocardial infarction, stroke (hemorrhagic and ischemic), hospitalization for acute coronary syndrome and urgent revascularization procedures and cardiovascular mortality. Secondary outcomes will be assessment of Carotid artery intima-media thickness (IMT); atherosclerotic plaque, flow-mediated dilatation (FMD); pulse wave velocity (PWV), brachial-ankle pulse wave velocity (bc), ankle-brachial pressure index (ABI), carotid atherosclerosis and carotid plaque. Network meta-analysis will be performed using multivariate random-effects meta-regression models. The surface under the cumulative ranking curve will be used to provide a hierarchy of statins that reduce cardiovascular mortality in CD patients. A revised version of the Cochrane Risk of Bias tool (RoB 2.0) will be used to assess the risk of bias in eligible RCTs. Results will be synthesized and analyzed using network meta-analysis (NMA). Overall strength of the evidence and publication bias will be evaluated.Ethics and dissemination: Ethics approval was not required for this study because it was based on published studies. The results and findings of this study will be submitted and published in a scientific peer-reviewed journal. PROSPERO registration number: CRD 42018083461Strengths and limitations of this study: To the best of our knowledge, this is the first systematic review with network meta-analysis that compares the cardiovascular safety of different classes of statins drugs based on data from both randomized clinical trials (RCTs) and observational studies.Common to most meta-analyses, significant and unexplained heterogeneity may exist. The protocol has been created according to the published PRISMA-P guidelines.Like any aggregate data meta-analysis, the risk for ecological fallacy exists and few RCTs may report data on cardiovascular mortality.

No abstract